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Abstract
Background: Cerebral microbleeds (MBs) are understood as an important radiologic marker of intracerebral hemorrhage.
We sought to investigate the temporal changes of MBs and clinical factors associated with the changes using long-term
follow-up MRI.
Methods/Principal Findings: From October 2002 to July 2006, we prospectively enrolled patients with stroke or transient
ischemic attack, and followed-up their brain MRIs with an interval .12 mo. We compared demographic factors, vascular risk
factors, laboratory findings, and radiologic factors according to the presence or changes of MBs. A total of 224 patients
successfully completed the follow-up examinations (mean, 27 months). Newly developed MBs were noted in 10 patients
(6.8%) among those without MBs at baseline (n=148), and in those with MBs at baseline (n=76), the MB count had
decreased in 11 patients (14.5%), and increased in 41 patients (53.9%). The estimated annual rate of change of MB numbers
was 0.80 lesions per year in all patients, a value which became greater in those patients who exhibited MBs at baseline
(MBs$5, 5.43 lesions per year). Strokes due to small vessel occlusion and intracerebral hemorrhage, as well as white matter
lesions were independently associated with an increased MB count, whereas the highest quartile of low-density lipoprotein
(LDL) cholesterol was associated with a decreased MB count.
Conclusion: During the follow-up period, most of MBs showed dynamic temporal change. Symptomatic or asymptomatic
small vessel diseases appear to act as risk factors while in contrast, a high level of LDL cholesterol may act as a protective
factor against MB increase.
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Introduction
Cerebral microbleeds (MBs), which are seen as small, focal, dark
signal intensity lesions on T2*-weighted gradient-echo magnetic
resonance imaging (MRI), pathologically represent the perivascu-
lar extravasation of blood resulting from advanced cerebral
microangiopathy, such as lipohyalinosis [1]. Old age [2], chronic
hypertension [3], left ventricular hypertrophy [4], low serum
cholesterol [5], and cerebral amyloid angiopathy [6] may be
associated with the presence or increase of MBs. Further these
lesions may be associated with the risks of future intracerebral
hemorrhage with numerical and regional associations [7], and
aspirin or warfarin-associated intracerebral hemorrhage [8,9], thus
serving a role as a risk factor or at least a radiological risk marker.
In addition, as hemorrhage-type microangiopathy, MBs are
positively correlated with the radiologic findings of ischemia-type
microangiopathy - silent lacunar infarction and white matter
lesions - in terms of the lesion extent; however, they are relatively
different in terms of spatial distribution [10]. Furthermore, it has
been suggested that MBs may play an active role in cognitive
function [11]. Generally, there is increasing evidence relating to
the importance of MB detection in various aspects of clinical
practice.
Despite its suggested importance, most previous studies have
been based on cross-sectional design which is questionable given
that the longitudinal temporal changes of MBs have yet to be
elucidated. In the current follow-up MRI study, we observed
temporal changes of MBs in a prospective series from a stroke
population, and attempted to determine factors associated with
lesion changes.
Methods
Study design
In order to elucidate the long-term temporal changes of MBs
after stroke or transient ischemic attack (TIA), we designed a
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enrolled stroke or TIA patients who had been admitted to the
stroke care unit of our hospital. We restricted the study
population to patients who had been admitted within seven days
of onset. At baseline, all patients underwent a complete set of
clinical tests – past medical history, neurological examination,
National Institutes of Health Stroke Scale (NIHSS) scoring, and
basic laboratory tests for stroke. Further, all patients received
standard stroke and best medical therapy during hospitalization.
Follow-up brain MRIs were conducted between December 2007
and February 2008, with an interval of at least 12 months from
the initial MRIs. If a patient had already undergone a brain MRI
due to various medical conditions in the six months prior to their
follow-up MRI visit, we did not perform the MRI again.
Conduction of follow-up MRI with an interval of 12 months after
stroke is covered by the National Health Insurance System in
Korea, and we obtained informed consents from the participants
verbally. We obtained medical information of the included
patients from the electronic medical record system of our
hospital. When lost to follow-up, we contacted the patient or
the family members by telephone to confirm their status. Despite
this effort, if a patient’s status could not be confirmed, we
classified the case as follow-up loss. In cases when the patient had
expired, the date and cause of death according to the
International Classification of Diseases (10th Revision), were
recorded. To confirm the accuracy of mortality information, we
matched our data to the nationwide official data on death
certification provided by the National Statistical Office, data
which have been used in previous studies as reliable data [12].
This study was approved by the Institutional Review Board of
Seoul National University Hospital (H-0805-035-243).
Determination of clinical variables and laboratory tests
We recorded demographic data (age and gender), conven-
tional risk factors, and important laboratory data for all subjects.
Conventional risk factors included hypertension, diabetes,
hyperlipidemia, and being a current smoker. Hypertension
was diagnosed as present if patients exhibited a systolic blood
pressure .140 mm Hg or a diastolic blood pressure .90 mm
Hg at discharge, or had a history of diagnosis of hypertension
and anti-hypertensive medications. Diabetes was diagnosed as
present if subjects exhibited a fasting glucose level $7.0 mmol/
L (126 mg/dL) or had a history of diagnosis of diabetes and
anti-diabetic medications. A diagnosis of hyperlipidemia was
made in patients with a history of using cholesterol-lowering
agents or who had a fasting serum total cholesterol level
.6.2 mmol/L (240 mg/dL) at admission. Body mass index was
calculated based on body weight and height (kg/m
2). With the
exception of hemorrhagic stroke, subtypes of ischemic stroke
were determined by consensus from a panel of stroke
neurologists the Trial of Org 10172 in Acute Stroke Treatment
(TOAST) criteria with minor modifications [13]. Fasting blood
samples were drawn within 24 hours of admission, and
examined using a standard battery of biochemical and
hematological tests. Lipid profiles included total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density lipopro-
tein cholesterol, and triglycerides.
Brain imaging protocols
Magnetic resonance images were obtained using a 1.5T
superconducting magnet (GE Medical Systems, Milwaukee, WI,
USA). In terms of protocol, the current study employed T2*-
weighted gradient-echo [repetition time/echo time (TR/TE),
500/15 ms; flip angle, 26u; slice thickness, 5 mm; matrix size,
2566192) and fluid-attenuated inversion recovery (FLAIR; TR/
TE, 8500/96 ms; inversion time, 2100 ms; flip angle, 26u; slice
thickness, 5 mm; matrix size, 2566192) imaging.
In accordance with the recommended criteria [1], the MBs
were defined as well-defined focal areas of dark signal intensity
measuring less than 5 mm in diameter with blooming artifacts on
gradient-echo MRI. We did not include lesions that were within
the subarachnoid space or areas of symmetric hypointensity of the
globus pallidus, given that they were likely to represent adjacent
pial blood vessels and calcification, respectively. The numbers of
the lesions were counted throughout the entire brain by two
neurologists (BJ Kim and CK Kim) who were blind to the clinical
characteristics.
White matter lesions were evaluated by FLAIR MRI, and
classified into four grades: Grade 0, no abnormality or minimal
periventricular signal hyperintensities in the form of caps confined
exclusively to the anterior horns or rims lining the ventricles;
Grade 1, hyperintensities in both the anterior and posterior horns
of the lateral ventricles or periventricular unifocal patches; Grade
2, multiple periventricular hyperintense punctate lesions and their
early confluence; and Grade 3, multiple areas of high signal
intensity reaching confluence in the periventricular region [14].
Statistical analysis
Means for continuous variables and proportions for categorical
variables were compared using student t-tests and x
2-tests as
appropriate. Data were expressed as means 6 standard deviation
(SD) or as numbers (percentages). To identify independent risk
factors for MBs at baseline, univariate and multivariate logistic
regression analysis was performed to calculate crude and adjusted
odds ratios (ORs) with 95% confidence intervals (CIs). In this
analysis, levels of lipid profiles were categorized into quartiles, and
the highest or lowest values were used as appropriate, given that
the relationships between values of lipid profiles and the presence
of MBs were not linear. For comparisons among multiple groups
from the patients with MBs at baseline (n=76), a one-way analysis
of variance (ANOVA) with Dunnett’s post-hoc comparisons was
used for continuous values, and the chi-square test was used for
categorical variables.
To examine temporal change of MB, we calculated annual
rates of change of MB counts by analyzing a mean of difference
between numbers of MBs at follow-up and numbers at initial
visit divided by the follow-up period (number of changes per
year). In addition, we used generalized estimating equations
(GEE) to evaluate the relationship between several predictor
variables related to MB count [15]. These equations were
necessary because of the clustered and correlated nature of
counting MBs using two individual brain MRIs longitudinally
over time. The repeated counting for each patient was treated as
ac l u s t e r .F u r t h e r ,G E Em o d e l sw e r ee s t i m a t e dt h a tu s e da n
exchangeable correlation matrix, assuming that outcomes for
individual MR imaging were equally correlated within each
patient but statistically independent between individuals. Uni-
variable and multivariable analyses was performed using GEE
models utilizing MB count as a dependent variable with Poisson
log-linear link function. Clinically relevant variables or poten-
tially significant variables from the univariate analyses (i.e.
p,0.1) were subsequently chosen to construct a multivariable
analysis model. Data produced by the GEE models were
presented as rate ratios (RRs) with 95% CIs. All statistical
analyses were conducted using SPSS for Windows, version 17.0
(SPSS Inc., Chicago, IL, USA), and statistical significance was
accepted at the p,0.05 level.
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Study population
Initially, 591 patients with acute stroke or TIA were screened
(Fig. 1). Among them, 165 patients refused participation in this
study, and thus, 426 patients represented the final number of
patients at baseline. Further, 32 patients (7.5%) were lost to follow-
up, and 76 patients (17.8%) could not undergo follow-up brain
MRI due to various medical reasons - irritability, claustrophobia,
decreased performance, unstable medical condition, concomitant
diseases, and patient delivery problem because of long distance
between the resident area and our center. In addition, 94 patients
(22.1%) expired during the study period. As a result, a total of 224
patients (52.6%) completed our study protocols and their data
were included in the final analysis.
Baseline characteristics
Among the 224 patients analyzed, there were 148 men (66.1%)
and 76 women (33.9%), and ages ranged from 31 to 95 years
(mean, 64.6611.3 years). Intervals between initial and follow-up
MRIs ranged from 12.0 to 62.6 months (mean, 27.5612.3
months). At baseline, there were 209 patients with stroke and 22
patients with TIA. Stroke subtypes were as follows: 58 large-artery
atherothromboses, 60 small-vessel occlusions, 33 cardioembolisms,
31 other determined or undetermined etiologies, and 20
intracerebral hemorrhages. On initial gradient-echo MRIs, 76
patients (33.9%) had cerebral MBs, and the numbers of MBs in
the whole brain area ranged 0 to 81 (mean per patient, 3.4610.5
lesions). When we compared the prevalence of MBs according to
stroke subtypes, the highest was in intracerebral hemorrhage
patients at 12 (57.1%). TIA represented the next highest
prevalence with 4 (26.4% in all TIA patients), followed by large-
artery atherothrombosis with 17 (28.8%), small-vessel occlusion
with 23 (37.7%), cardioembolism with 9 (28.1%), and 8 with other
determined or undetermined etiologies (26.7%). Baseline charac-
teristics have been provided in Table 1. The patients with MBs at
baseline showed a higher frequency of hypertension, lower
frequency of diabetes, and lower levels of hemoglobin A1c than
those patients without MBs.
Association factors for the presence of MBs at baseline
Using multivariable logistic regression analysis, we sought to
determine factors associated with the presence of MBs at baseline.
We entered demographic variables, vascular risk factors, some of
initial laboratory findings (lipid profiles, hemoglobin A1c, and
creatinine), and radiological findings (white matter lesions) after
assuming that such laboratory findings and white matter lesions
went unchanged after insult of stroke. The presence of diabetes
was independently, but negatively associated with the presence of
MBs (adjusted OR, 0.44; 95% CI, 0.22–0.90), whereas the severity
of white matter lesions was a strong risk factor (adjusted OR, 2.32;
95% CI, 1.59–3.39).
Long-term temporal changes of MBs
Generally, there was an increasing trend of MBs during the
study period. There was no patient, in which MBs at baseline
completely disappeared at follow-up, whereas 10 patients (6.8%)
among the patients without MBs at baseline (n=148) had newly
developed MBs at follow-up. Thus, a total of 86 patients had MBs
at follow-up (38.4%), with the total number of MBs increasing by
about 1.5-fold (mean, 4.9616.8 lesions). Among the 76 patients
with MBs at baseline, the numbers of MBs decreased in 11 (14.5%)
Figure 1. Flow chart for the study sample.
doi:10.1371/journal.pone.0025930.g001
Table 1. Baseline characteristics of patients according to
presence of MBs at baseline.
MBs at baseline
Absent (n=148) Present (n=76)
Gender (men) 96 (64.9%) 52 (68.4%)
Age, years 64.8611.2 64.5611.5
Body mass index 23.863.1 23.563.1
Hypertension* 95 (64.2%) 59 (77.6%)
Diabetes* 60 (40.5%) 17 (22.4%)
Hyperlipidemia 27 (18.2%) 12 (15.8%)
Smoking 30 (20.3%) 16 (21.1%)
TIA 13 (8.8%) 9 (11.8%)
Stroke 135 (91.2%) 67 (88.2%)
NIHSS scores at baseline 2.162.1 2.865.0
Total cholesterol, mg/dL 183.9646.4 175.3639.7
LDL cholesterol, mg/dL 112.9639.2 107.7639.7
HDL cholesterol, mg/dL 44.8612.6 41.7611.8
Triglyceride, mg/dL 128.8683.3 130.4692.5
Hemoglobin A1c, %* 6.661.6 6.061.3
Creatinine, mg/dL 1.160.9 1.361.2
MBs, numbers 0 9.9616.0
MB indicates microbleed; TIA, transient ischemic attack; NIHSS, National
Institute of Health Stroke Scale; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; NS, not significant.
Student t-tests or x
2 tests were used.
*indicates p,0.05.
doi:10.1371/journal.pone.0025930.t001
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remaining 24 (31.6%) patients were unchanged during the follow-
up. Examples of dynamic temporal changes of MB have been
provided in Fig. 2.
Table 2 and 3 provide the characteristics of these 76 patients
with MBs at baseline. Using an ANOVA with post-hoc tests for
intra- and inter-group comparisons, we found that those with
decreased numbers of MBs exhibited higher total and LDL
cholesterol levels at baseline (p=0.030 and 0.018, respectively),
and higher usage of angiotensin-converting enzyme inhibitors or
angiotensin-receptor blockers (p=0.027).
Estimated annual change rates of MB numbers are revealed in
Table 4. The rate of increase in the number of MBs was about 0.8
lesions per year in all patients, a value which increased when we
restricted our analysis only to those patients with MBs at baseline.
The rate of increase in patients without MB at baseline was very
small (0.04 lesions per year).
Predictors of temporal changes of MBs
We used the GEE models to find predictors of temporal changes
of MBs. Based on the univariable analyses, age and grades of white
matter lesions were identified as predictors for increasing MB
count, and diabetes, hyperlipidemia, the highest quartile of LDL-
cholesterol, and the highest quartile of triglyceride during the
follow-up period were documented as predictors for decreasing
number of MBs (Table 5). Compared to stroke due to other types
or transient ischemic attack, it was determined that small vessel
occlusion and intracerebral hemorrhage were strongly associated
with MB count. Based on the multivariable analyses performed to
identify predictor variables for MB count over time, strokes due to
small vessel occlusion and intracerebral hemorrhage, the highest
quartile of LDL-cholesterol, and white matter lesions were
determined to be independently associated with MB count
(Table 6).
Discussion
In this follow-up study, we found that temporal change in MB
counts was dynamic with the total number of MBs increasing by
1.5-fold over time. The rate of change in MB counts was 0.80
lesions per year in all patients, and became much greater in
patients with MBs at baseline. Specifically, this increasing trend
was about 60-fold greater in patients with MBs at baseline than in
patients without. Additionally, the presence of diabetes was
negatively associated with the presence of MBs at baseline,
whereas severity of white matter lesions was a strong risk factor.
With regard to the change in MB counts during follow-up, strokes
due to small vessel occlusion and intracerebral hemorrhage and
white matter lesions were identified as independent risk factors,
whereas the highest quartile of LDL cholesterol was identified as
an independent protective factor.
MBs are closely associated with incident or recurrent intrace-
rebral hemorrhage among the stroke subtypes, and it has been
noted that the presence or number of MBs is the most important
radiologic marker of a cerebral bleeding tendency due to small
Figure 2. Dynamic changes of MBs over a long-term MRI follow-up. Some new MBs appeared (A), and some MBs disappeared in the follow-
up MRI (B). Black arrows represent the MRI follow-up, while white arrow heads indicate new MBs, and dotted circles identify the location of those MBs
which had disappeared.
doi:10.1371/journal.pone.0025930.g002
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Number of MBs
Decrease (n=11) No change (n=24) Increase (n=41)
Demographic Gender (men) 6 (54.5%) 16 (66.7%) 30 (73.2%)
Age, years 61.1613.5 62.5610.4 66.6611.4
Body mass index 23.763.5 24.262.5 22.963.3
Vascular risk factors Hypertension 9 (81.8%) 19 (79.2%) 31 (75.6%)
Diabetes 4 (36.4%) 5 (20.8%) 8 (19.5%)
Hyperlipidemia 2 (18.2%) 5 (20.8%) 5 (12.2%)
Smoking 4 (36.4%) 4 (16.7%) 8 (19.5%)
Clinical profiles TIA 0 (0%) 4 (16.7%) 5 (12.2%)
Stroke 11 (100%) 20 (83.3%) 36 (87.4%)
NIHSS scores at baseline 2.262.9 2.461.9 3.166.4
Stroke subtypes Small vessel occlusion 4 (36.4%) 7 (29.2%) 12 (29.3%)
Large artery atherosclerosis 3 (27.3%) 7 (29.2%) 6 (14.6%)
Cardioembolism 2 (18.2%) 2 (8.3%) 5 (12.2%)
UD or OD 0 (0%) 1 (4.2%) 7 (17.1%)
Intracerebral hemorrhage 2 (18.2%) 3 (12.5%) 6 (14.6%)
MB indicates microbleed; TIA, transient ischemic attack; NIHSS, National Institute of Health Stroke Scale; UD, undetermined; OD, other determined; ANOVA tests with
Dunnett’s post-hoc analysis or x
2 tests were used, but there were no significant results.
doi:10.1371/journal.pone.0025930.t002
Table 3. Baseline characteristics of patients according to temporal change of MBs counts during follow-up: part 2.
Number of MBs
Decrease (n=11) No change (n=24) Increase (n=41)
Laboratory findings Total cholesterol, mg/dL{ 201.7631.7 171.1639.4 179.7640.0
LDL cholesterol, mg/dL*{ 133.5623.5 104.3635.5 102.8631.7
HDL cholesterol, mg/dL 41.667.2 42.4612.4 41.3612.7
Triglyceride, mg/dL 138.0670.3 123.5693.8 132.4698.4
Hemoglobin A1c, % 6.561.2 6.061.2 6.061.3
Creatinine, mg/dL 1.160.3 1.160.5 1.561.5
Radiologic findings White matter lesions, grade 2 (18.2%) 4 (16.7%) 7 (17.1%)
Grade 0 2 (18.2%) 14 (58.3%) 13 (31.7%)
Grade 1{1 4 (36.4%) 5 (20.8%) 10 (24.4%)
Grade 2 3 (27.3%) 1 (4.2%) 11 (26.8%)
Grade 3{1 2 (18.2%) 4 (16.7%) 7 (17.1%)
Medications ACEIs/ARBs{ 9 (81.8%) 10 (41.7%) 18 (43.9%)
CCBs 4 (36.4%) 6 (25.0%) 7 (17.1%)
Beta-blockers 2 (18.2%) 6 (25.0%) 10 (24.4%)
Diuretics 7 (63.6%) 14 (58.3%) 10 (24.4%)
Statins 4 (36.4%) 6 (25.0%) 12 (29.3%)
Antiplatelet agents 6 (54.5%) 19 (79.2%) 29 (70.7%)
Anticoagulation 2 (18.2%) 2 (8.3%) 8 (19.5%)
Oral hypoglycemic agents 2 (18.2%) 3 (12.5%) 4 (9.8%)
LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker.
ANOVA tests with Dunnett’s post-hoc analysis or x
2 tests were used:
*indicates p,0.05 from overall comparisons;
{, p,0.05 from post-hoc analysis between ‘‘decreased’’ and ‘‘no change’’;
1, p,0.05 from post-hoc analysis between ‘‘increased’’ and ‘‘no change’’.
doi:10.1371/journal.pone.0025930.t003
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lesions in the elderly has rarely been reported. A recent report
examined 21 patients with ischemic stroke or TIA over an average
of 5.5 years [18]. Their results showed that those with new MBs
represented 50% of the patients with MBs at baseline (4 out of 8
patients); however, only 8% of patients without (1 out of 13
patients). In the present study, we showed that new MBs were
found in 53.9% of patients with MBs at baseline (41 out of 76
patients), but only in 6.8% of patients without (10 out of 148
patients). Considering a follow-up period of 27 months, the
current results regarding temporal change of MBs after ischemic
stroke or TIA are in line with previous studies. Additionally, the
great discrepancy regarding the increased incidence of MBs in
patients with MBs at baseline as compared to those without MBs is
very similar to the results from the PROGRESS MRI sub-study
on temporal change of white matter lesions after ischemic stroke
[19]. Ischemic stroke and TIA are frequently found in elderly
people, and share substantial pathophysiological mechanisms
although representing two different aspects of small vessel disease
(ischemia vs. hemorrhage) [20,21]. Results both from our study
and the PROGRESS sub-study demonstrate that presence of
small vessel disease at baseline itself may be crucial in progress of
the small vessel disease [19]. Our results suggest that in patients
with even a single MB, caution should be taken in their
management, with special attention paid to the incidence of
intracerebral hemorrhage.
We and others have previously shown that low concentrations
of serum cholesterol are associated with the severe MBs, suggesting
the antagonizing role of cholesterol in MB pathogenesis [5,22]. In
the present study, we found that the highest quartile of LDL
cholesterol was independently associated with a decrease in MB
counts during the follow-up. In fact, many large cohort studies
have demonstrated that low serum levels of total cholesterol may
represent a risk factor for intracerebral hemorrhage, especially in
Japan [23,24,25,26]. A similar inverse relationship was reported
between serum total cholesterol level and the risk of death from
hemorrhagic stroke in western countries [27]. Considering the
pathology of MB (hemosiderin pigment accumulations in
macrophages adjacent to the ruptured atherosclerotic microves-
sels) [21], the disappearance of MBs might depend on the
clearance of hemosiderin-containing macrophages. Because MBs
are frequently associated with microaneurysms [28], any changes
related to hemosiderin-containing microaneurysms may be
associated as well. It was hypothesized that high levels of LDL
cholesterol were likely to prevent small vessel rupture in the brain
[5,29,30]; however, there has been no evidence that high level of
LDL cholesterol can enhance the clearance of hemosiderin-
containing microglia. Taken together, these hypotheses warrant
further confirmation studies.
Despite the accumulation of evidence on cholesterol and
bleeding, association between the use of lipid-lowering therapy
such as statin and the occurrence of cerebral bleeding episodes has
been controversial. Only one report has indicated that intensive
lipid-lowering after stroke significantly increased the incidence of
intracerebral hemorrhage [31], whereas other statin studies have
produced contradictory. While many issues exist (primary or
secondary prevention of stroke, stroke subtypes, and risk factor
burden, etc), systematic reviews on this topic show inconsistent
conclusions [32,33]. Therefore, the effects of low levels of LDL
cholesterol on the brain should be further investigated in terms of
the nature of the low level - intrinsic low level vs. low level
therapeutically intervened by statin.
Table 4. Estimated annual rates of change of MB counts.
Patients
Annual rate of change of
MB counts (lesions per year)
Total patients (n=224) 0.8063.80
MBs at baseline=0 (n=148) 0.0460.14
MBs at baseline$1 (n=76) 2.3066.28
MBs at baseline$2 (n=55) 3.0067.25
MBs at baseline$5 (n=28) 5.4369.59
MB indicates microbleed.
doi:10.1371/journal.pone.0025930.t004
Table 5. Univariable analysis using the GEE model.
Crude RR 95% CI
Gender (men) 1.21 0.53–2.77
Age (per 1-year increase) 1.04 1.01–1.07
Body mass index (per 1-kg/m
2 increase) 0.97 0.85–1.12
Hypertension 1.67 0.52–5.29
Diabetes 0.32 0.13–0.76
Hyperlipidemia 0.35 0.13–0.97
Smoking 0.79 0.22–2.86
Small vessel occlusion 2.77 1.15–6.68
Intracerebral hemorrhage 4.72 1.61–13.84
NIHSS at admission (per 1-point increase) 0.99 0.89–1.10
Total cholesterol (4th quartile vs. others) 0.27 0.13–0.55
LDL-cholesterol (4th quartile vs. others) 0.23 0.11–0.49
HDL-cholesterol (1st quartile vs. others) 1.14 0.40–3.23
Triglyceride (4th quartile vs. others) 0.18 0.09–0.37
Hemoglobin A1c (per 1% increase) 0.79 0.67–0.94
Creatinine (per 1 mg/dL increase) 1.00 0.86–1.17
White matter lesions (per 1-grade increase) 2.78 1.62–4.78
ACEIs or ARBs 1.17 0.50–2.73
CCBs 0.71 0.32–1.56
Beta-blockers 1.77 0.68–4.60
Diuretics 1.30 0.44–3.83
Statins 0.90 0.32–2.56
Antiplatelet agents 0.81 0.33–2.01
Anticoagulation 0.60 0.23–1.57
GEE indicates generalized estimating equations; RR, rate ratio; CI, confidence
interval; NIHSS, National Institute of Health Stroke Scale; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin-receptor blocker.
doi:10.1371/journal.pone.0025930.t005
Table 6. Multivariable analysis using the GEE model.
Adjusted RR 95% CI
Small vessel occlusion 2.49 1.15–5.40
Intracerebral hemorrhage 4.06 1.01–16.32
LDL-cholesterol (4
th quartile vs others) 0.30 0.14–0.68
White matter lesions (per 1-grade increase) 2.39 1.27–4.53
doi:10.1371/journal.pone.0025930.t006
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vessel occlusion and intracerebral hemorrhage as baseline stroke
subtypes with an increase in MB counts. This result confirms that
MBs are produced by advanced cerebral small vessel disease
[10,21]. Moreover, an association with small vessel occlusion, that
is lacunar infarction, indicates caution should be taken with
intensive long-term anti-thrombotic therapy in such patients.
There are some caveats to this study. First, in general, diabetes
is not a risk factor for intracerebral hemorrhage [34]. In this study,
the presence of diabetes was a protective factor for presence of
MBs at baseline, but this association was not replicated in the
follow-up analysis. It has been reported that diabetes tends to
increase large artery atherosclerosis rather than small vessel
occlusion [35,36]; however, this suggestion was not supported
here. The biological effects of diabetes on the brain vascular
system need to be clarified. Second, from the initial population, 90
patients expired and thus, a suitable follow-up was not possible. It
is possible that the deceased patients may have demonstrated a
greater change in MB count than those patients that lived through
the follow-up period. If we had performed frequent brain MRIs,
we would have shown more a precise temporal course; however,
this study design did not allow for that due to ethical and
economical considerations. Thus, our study results may be
interpreted for surviving patients during the follow up period
after ischemic stroke and TIA.
Our results showed that long-term temporal change of MBs
after ischemic stroke is dynamic, and that this dynamicity is largely
affected by the initial appearance of MBs. Further, changes in MB
count may be associated with small vessel disease and the level of
LDL cholesterol. Our results provide an effective basis for further
MB studies. Recent recognition of the effect of MB on cognitive
decline indicates that MBs are no longer a ‘‘silent’’ lesion. Thus,
dynamic changes in MB counts should be further investigated in
terms of their effects on cognitive function as well as on other
vascular events.
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